1. Patients who were enrolled and treated in Studies A8081005, A8081007, A8081014,
A8081029, or A8081063 and are still receiving crizotinib treatment at the time of
enrollment into this study. OR Patients randomized to the chemotherapy arm in Studies
A8081014 or A8081029 who have experienced investigator assessed disease progression
and have not yet crossed over to receive crizotinib treatment.
2. No ongoing NCI CTCAE Grade 3 or intolerable Grade 2 adverse events considered to be
related to crizotinib treatment
3. Eastern Cooperative Oncology Group (ECOG) performance status 0-3
4. Adequate organ function as defined by the following criteria
1. Use of any anticancer drug subsequent to crizotinib prior to study entry
2. Use of drugs or foods that are known potent Cytochrome P450 (CYP)3A4 inhibitors
3. Use of drugs that are known potent CYP3A4 inducers
4. Concurrent use of drugs that are CYP3A4 substrates with narrow therapeutic indices,
associated with life threatening arrhythmias